Miles D, Ciruelos E, Schneeweiss A, Puglisi F, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol 2021 Jul 2. pii: S0923-7534(21)02105.
PMID: 34224826